Skip to content
Qualio Home Page

Our Blog

The Qualio Blog

Insights on product development, quality management, and regulatory compliance for teams building life-saving products.

Lola Furlong

If Compliance Is Slowing You Down, Your Regulations Are Not the Problem. Your Model Is.

The medical device industry has accepted a false tradeoff. Here's how the best MedTech companies are rejecting it.

Compliance
Meg Sinclair

Why Hiring More QA Staff Won't Solve Your Biotech Compliance Capacity Problem

Hiring more QA staff doesn't solve biotech compliance capacity problems — it masks them. Learn why compliance complexity outpaces headcount, and what a continuous compliance execution model actually looks like.

Biotech
Lola Furlong

6 Signs You're Going to Break at IND: And Don't Know It Yet

Pre-IND biotech teams often mistake a clean GLP audit for clinical readiness. These six structural warning signs reveal whether your quality system is built for clinical demands or running on heroics before IND exposes the gap.

Quality management
Sumatha Kondabolu

The Compliance Architecture Problem Biotech Companies Don't See Coming

Most biotech companies don't fail because of bad science. They miss timelines because of how they've built their compliance infrastructure — not the people, not the intent. The architecture.

Biotech
Lola Furlong

Episodic vs. Continuous Readiness: Which Operating Model Is Carrying Your Biotech Forward?

Most growth-stage biotech companies are audit-ready. Far fewer are scale-ready. Learn the difference between episodic and continuous readiness — and why it determines your clinical outcomes.

Biotech
Sumatha Kondabolu

CDSCO Medical Device Registration in India: What's Changed in 2026 (And What Still Applies)

CDSCO has moved fast since 2024. This 2026 update covers new SaMD software guidance, three FAQ addenda, post-approval change clarity, and the BIS Scheme X deadline — everything you need before entering the Indian medical device market.

Compliance
Sumatha Kondabolu

The Structural Limits of Generic GRC in Modern Life Sciences

Generic GRC platforms were built for corporate risk — not regulated product lifecycles. Learn why life sciences organizations outgrow them, and what a purpose-built compliance architecture actually looks like.

Medical Devices
Lola Furlong

Regulation Is Not Slowing Your Medical Device. Your Compliance Architecture Is.

FDA oversight isn't why MedTech product development slows down. Fragmented compliance architecture is. Here's what that costs—and what a better system looks like.

Medical Devices
Meg Sinclair

The Work That Never Shows Up in Your QA Plan

Most biotech QA teams aren't short on people, they're short on capacity. Learn where the hours actually go, and what it's costing your clinical program.

Quality Management